Cargando…
Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
BACKGROUND: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. METHODS: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patien...
Autores principales: | Duarte, Mariano, Pelorosso, Facundo, Nicolosi, Liliana N., Victoria Salgado, M., Vetulli, Héctor, Aquieri, Analía, Azzato, Francisco, Castro, Marcela, Coyle, Javier, Davolos, Ignacio, Criado, Ignacio Fernandez, Gregori, Rosana, Mastrodonato, Pedro, Rubio, María C., Sarquis, Sergio, Wahlmann, Fernando, Rothlin, Rodolfo P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225700/ https://www.ncbi.nlm.nih.gov/pubmed/34189447 http://dx.doi.org/10.1016/j.eclinm.2021.100962 |
Ejemplares similares
-
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
por: Rothlin, Rodolfo Pedro, et al.
Publicado: (2023) -
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
por: Rothlin, Rodolfo Pedro, et al.
Publicado: (2021) -
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen
por: Ibarrola, Martin, et al.
Publicado: (2020) -
Telmisartan and cardioprotection
por: Akhrass, Philippe R, et al.
Publicado: (2011) -
Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats
por: Lezcano, Eduardo J, et al.
Publicado: (2014)